US5164407A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
Assignee: Merck and Co Inc
•
Filing: 1990-04-25
•
Granted: 1992-11-17
•
Expires: 2010-04-25
Abstract
Abstract There are disclosed new substituted imidazo-fused 5-membered ring heterocyclic compounds and derivatives thereof which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1##
Inventors
- 👤 William J. Greenlee
- 👤 David B. R. Johnston
- 👤 Malcolm MacCoss
- 👤 Nathan B. Mantlo
- 👤 Arthur A. Patchett
- 👤 Prasun K. Chakravarty
- 👤 Thomas F. Walsh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 16:21
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04; A; A61; A61P; A61P27/00; A61P27/02; A61P43/00; A61P9/00; A61P9/08; A61P9/10; A61P9/12; C07D491/00; C07D491/02; C07D491/04; C07D495/00; C07D495/02; C07D495/04
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
474 words
A compound having the formula: ##STR55## or a pharmaceutically acceptable salt thereof wherein: R 1 is (a) --COOH, (b) --SO 2 NH-heteroaryl as defined below, (c) --CH 2 SO 2 NH-heteroaryl as defined below, (d) --SO 2 NH--CO--R 21 , (e) --CH 2 SO 2 NH--CO--R 21 , (f) --CONH--SO 2 R 21 , (g) --CH 2 CONH--SO 2 R 21 , (h) --NHSO 2 NHCO--R 21 , (i) --NHCONHSO 2 R 21 , (j) --SO 2 NHCONHR 21 , ##STR56## wherein: heteroaryl is an unsubstituted, monosubstituted or disubstituted five-membered aromatic ring which can contain from 1 to 3 nitrogen atoms and wherein the substituents are members selected from the group consisting of --OH, --SH, --C 1 -C 4 -alkyl, --C 1 -C 4 -alkoxy, --CF 3 , halo(Cl, Br, F, I), --NO 2 , --CO 2 H, --CO 2 -C 1 -C 4 -alkyl, --NH 2 , NH(C 1 -C 4 -alkyl) and --N(C 1 -C 4 -alkyl) 2 ; R 2a is H; R 2b is H, Cl, C 1 -C 4 -alkyl, or C 1 -C 4 -alkoxy; R 3a is H, R 3b is (a) H, (b) Cl, (c) C 1 -C 4 -alkyl, (d) C 5 -C 6 -cycloalkyl, or (e) C 1 -C 4 -alkoxy; wherein aryl is phenyl or naphthyl optionally substituted with one or two substituents selected from V and W as defined below; R 4 is H or C 1 -C 4 -alkyl; E is a single bond; R 6 is C 1 -C 5 -alkyl; A--B--C together are: (a) --C(R 7a )═C(R 7b )--Y--, (b) --Y--C(R 7a )═C(R 7b )--; Y is S; R 7a and R 7b are independently: (a) H; (b) straight chain or branched C 1 -C 6 -alkyl, which is optionally substituted with OH, CO 2 R 4 , N(R 4 ) 2 or CON(R 4 ) 2 ; (c) aryl or aryl-C 1 -C 4 -alkyl wherein the aryl can be optionally substituted with H, halo, C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or CO 2 R 4 ; (d) CO 2 R 4 ; (e) CON(R 4 ) 2 ; (f) halo (Cl, Br, F, I); R 21 is (a) aryl as defined above, (b) heteroaryl as defined above, (c) C 3 -C 7 -cycloalkyl; X is: (a) a single bond, (b) --CO--, (c) --O--, (d) --S--, ##STR57## (h) --OCH 2 , (i) --CH 2 O--, (j) --SCH 2 --, (k) --CH 2 S--, (l) --NHC(R 9 )(R 10 )--, (m) NR 9 SO 2 --, (n) --SO 2 NR 9 --, (o) --C(R 9 )(R 10 )NH--, (p) --CH═CH--, (q) --CF═CF--, (r) --CH═CF--, (s) --CF═CH--, (t) --CH 2 CH 2 --, (u) --CF 2 CF 2 --, ##STR58## Z is NR 13 ; and r is 1 or 2.
Claim 2
Dependent Claim
474 words
A compound having the formula: ##STR55## or a pharmaceutically acceptable salt thereof wherein: R 1 is (a) --COOH, (b) --SO 2 NH-heteroaryl as defined below, (c) --CH 2 SO 2 NH-heteroaryl as defined below, (d) --SO 2 NH--CO--R 21 , (e) --CH 2 SO 2 NH--CO--R 21 , (f) --CONH--SO 2 R 21 , (g) --CH 2 CONH--SO 2 R 21 , (h) --NHSO 2 NHCO--R 21 , (i) --NHCONHSO 2 R 21 , (j) --SO 2 NHCONHR 21 , ##STR56## wherein: heteroaryl is an unsubstituted, monosubstituted or disubstituted five-membered aromatic ring which can contain from 1 to 3 nitrogen atoms and wherein the substituents are members selected from the group consisting of --OH, --SH, --C 1 -C 4 -alkyl, --C 1 -C 4 -alkoxy, --CF 3 , halo(Cl, Br, F, I), --NO 2 , --CO 2 H, --CO 2 -C 1 -C 4 -alkyl, --NH 2 , NH(C 1 -C 4 -alkyl) and --N(C 1 -C 4 -alkyl) 2 ; R 2a is H; R 2b is H, Cl, C 1 -C 4 -alkyl, or C 1 -C 4 -alkoxy; R 3a is H, R 3b is (a) H, (b) Cl, (c) C 1 -C 4 -alkyl, (d) C 5 -C 6 -cycloalkyl, or (e) C 1 -C 4 -alkoxy; wherein aryl is phenyl or naphthyl optionally substituted with one or two substituents selected from V and W as defined below; R 4 is H or C 1 -C 4 -alkyl; E is a single bond; R 6 is C 1 -C 5 -alkyl; A--B--C together are: (a) --C(R 7a )═C(R 7b )--Y--, (b) --Y--C(R 7a )═C(R 7b )--; Y is S; R 7a and R 7b are independently: (a) H; (b) straight chain or branched C 1 -C 6 -alkyl, which is optionally substituted with OH, CO 2 R 4 , N(R 4 ) 2 or CON(R 4 ) 2 ; (c) aryl or aryl-C 1 -C 4 -alkyl wherein the aryl can be optionally substituted with H, halo, C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy or CO 2 R 4 ; (d) CO 2 R 4 ; (e) CON(R 4 ) 2 ; (f) halo (Cl, Br, F, I); R 21 is (a) aryl as defined above, (b) heteroaryl as defined above, (c) C 3 -C 7 -cycloalkyl; X is: (a) a single bond, (b) --CO--, (c) --O--, (d) --S--, ##STR57## (h) --OCH 2 , (i) --CH 2 O--, (j) --SCH 2 --, (k) --CH 2 S--, (l) --NHC(R 9 )(R 10 )--, (m) NR 9 SO 2 --, (n) --SO 2 NR 9 --, (o) --C(R 9 )(R 10 )NH--, (p) --CH═CH--, (q) --CF═CF--, (r) --CH═CF--, (s) --CF═CH--, (t) --CH 2 CH 2 --, (u) --CF 2 CF 2 --, ##STR58## Z is NR 13 ; and r is 1 or 2.
Claim 3
Dependent Claim
43 words
The compound of claim 1 which is a member of the group: (1) 6-methyl-2-propyl-3-[(2'-{1H-tetrazol-5-yl}-{1,1'-biphenyl}-4-yl)methyl]-3H-thieno[2,3-d]imidazole-5-methanol; (2) 2-butyl-6-methyl-3-[(2'-{1H-tetrazol-5-yl}{1,1'-biphenyl}-4-yl)methyl]-3H-thieno[2,3-d]imidazole-5-carboxylic acid; (3) 2-butyl-1-[(2'-{1H-tetrazol-5-yl}{1,1'-biphenyl}-4-yl)methyl]-1H-thieno[2,3-d]imidazole-5-carboxylic acid methyl ester; (4) 2-butyl-3-[(2'-carboxy{1,1'-biphenyl}-4-yl)-methyl]-3H-thieno[2,3-d]imidazole-5-carboxylic acid methyl ester; (5) 2-butyl-3-[(2'-{1H-tetrazol-5-yl}{1,1'-biphenyl}-4-yl)methyl]-3H-thieno[2,3-d]imidazole-5-carboxylic acid methyl ester; (6) 2-butyl-1-[(2'-{1H-tetrazol-5-yl}{1,1'-biphenyl}-4-yl)methyl]-1H-thieno[2,3-d]imidazole-5-carboxylic acid methyl ester; and, (7) 2-butyl-1-[(2'-{(N-phenlsulfonyl)carboxamido}{1,1'-biphen}-4-yl)methyl]-1H-thieno[2,3-d]-imidazole-5-carboxylic acid methyl ester.
Claim 4
Dependent Claim
26 words
A pharmaceutical composition useful in the treatment of hypertension which comprises a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.
Claim 5
Dependent Claim
26 words
A method of treating hypertension which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-17 | 1996-05-18 | 1996-11-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-17 | 2000-05-18 | 2000-11-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-17 | 2004-05-18 | 2004-11-17 | $7700.00 | Window Closed / Lapsed |